Compare IMMR & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMMR | AGEN |
|---|---|---|
| Founded | 1993 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 216.7M | 124.4M |
| IPO Year | 1999 | 1999 |
| Metric | IMMR | AGEN |
|---|---|---|
| Price | $5.60 | $3.42 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $13.50 | ★ $14.50 |
| AVG Volume (30 Days) | 390.4K | ★ 499.8K |
| Earning Date | 02-27-2026 | 03-16-2026 |
| Dividend Yield | ★ 5.50% | N/A |
| EPS Growth | 82.69 | ★ 100.00 |
| EPS | N/A | ★ N/A |
| Revenue | $35,013,000.00 | ★ $42,877,086.00 |
| Revenue This Year | N/A | $61.42 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $8.89 |
| Revenue Growth | N/A | ★ 89.95 |
| 52 Week Low | $5.25 | $1.38 |
| 52 Week High | $8.15 | $7.34 |
| Indicator | IMMR | AGEN |
|---|---|---|
| Relative Strength Index (RSI) | 37.89 | 51.04 |
| Support Level | N/A | $2.91 |
| Resistance Level | $7.08 | $4.66 |
| Average True Range (ATR) | 0.24 | 0.26 |
| MACD | -0.07 | -0.03 |
| Stochastic Oscillator | 26.94 | 42.37 |
Immersion Corp is focused on the creation, design, development, and licensing of haptic technologies that allow people to use its sense of touch more fully as it involves engaging with products and experience the digital world. The company's software focuses on applications in mobile devices, wearables, consumer, and gaming devices markets. It generates revenue from royalty and license fees, and development contract and service fees. Geographically, the company generates a majority of its revenue from Japan, followed by Korea, Germany, United States of America and other countries.
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.